Original article Continuing trends in pathological stage migration in radical prostatectomy specimens
暂无分享,去创建一个
I. Derweesh | H. Levin | C. Magi-Galluzzi | E. Klein | J. Myles | C. Zippe | P. Kupelian | J. Brainard | Alwyn M. Reuther
[1] R. Peschel,et al. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. , 2003, The Lancet. Oncology.
[2] Laurence R. Paquette,et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.
[3] A. Renshaw,et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.
[4] M. Kattan,et al. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Levin,et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Stamey,et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. , 1998, The Journal of urology.
[7] H. Levin,et al. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. , 1998, Urology.
[8] M. Kattan,et al. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? , 1997, The Journal of urology.
[9] A. Partin,et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.
[10] H. Levin,et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.
[11] C. Smart,et al. The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence‐‐Data from the Utah Cancer Registry , 1996, Cancer.
[12] A. Partin,et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.
[13] H. Adami,et al. The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913. , 1995, The Journal of urology.
[14] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[15] P. Knekt,et al. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.
[16] P. Scardino,et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.
[17] J. Oesterling,et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.
[18] W. Catalona,et al. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.
[19] R. Kane,et al. Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .
[20] W. Catalona,et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.
[21] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[22] E. Klein,et al. Early continence after radical prostatectomy. , 1992, The Journal of urology.
[23] E. Metter,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.
[24] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[25] J. Oesterling,et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.
[26] R L Vessella,et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.
[27] T. Stamey,et al. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .
[28] I. Thompson,et al. Adenocarcinoma of the prostate: results of routine urological screening. , 1984, The Journal of urology.
[29] G. Murphy,et al. The national survey of prostate cancer in the United States by the American College of Surgeons. , 1982, The Journal of urology.
[30] Laurence R. Paquette,et al. Predictors of extracapsular extension and positive margins in African American and white men. , 2003, Urologic oncology.
[31] R. Kane,et al. The results of a five‐year early prostate cancer detection intervention , 1996, Cancer.